CGEM
Cullinan Therapeutics, Inc. · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 77 | +7 | 28.05M | $510.52M | +11 | −4 |
| Q1 2026 | 73 | +7 | 24.59M | $348.81M | +10 | −3 |
| Q4 2025 | 65 | +1 | 21.69M | $224.52M | +1 | — |
| Q3 2025 | 17 | +1 | 15.39M | $91.26M | +1 | — |
| Q2 2025 | 13 | 0 | 14.48M | $109.06M | +1 | −1 |
| Q1 2025 | 10 | -1 | 7.69M | $58.25M | — | −1 |
| Q4 2024 | 11 | 0 | 8.98M | $109.41M | — | — |
| Q3 2024 | 10 | +1 | 6.86M | $114.80M | +1 | — |
| Q2 2024 | 9 | — | 7.12M | $124.19M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Adage Capital Partners ✦ | 2.23M | — | $38.94M | 0.1% | n/c | 1 | SEC ↗ |
| 2 | Citadel Advisors ✦ | 1.94M | — | $33.89M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Marshall Wace ✦ | 1.18M | — | $20.65M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 976.49K | — | $17.03M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Geode Capital Management ✦ (passive) | 976.49K | — | $17.03M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Renaissance Technologies ✦ | 421.71K | — | $7.35M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | D. E. Shaw & Co. ✦ | 212.45K | — | $3.71M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Wellington Management ✦ | 72.10K | — | $1.26M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | Wellington Management ✦ | 72.10K | — | $1.26M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | Two Sigma Investments ✦ | 57.36K | — | $1.00M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | T. Rowe Price ✦ | 20.80K | — | $363,000 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 172 holders, 65.27M shares, $895.39M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 30.00K sh · $607,800
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology